Principal Financial Group Inc. Boosts Stake in Charles River Laboratories Intl. Inc (NYSE:CRL)

Principal Financial Group Inc. boosted its holdings in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 1.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 215,125 shares of the medical research company’s stock after buying an additional 3,228 shares during the period. Principal Financial Group Inc.’s holdings in Charles River Laboratories Intl. were worth $31,247,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Charles River Laboratories Intl. by 1.3% in the first quarter. BlackRock Inc. now owns 4,587,801 shares of the medical research company’s stock valued at $666,379,000 after buying an additional 57,789 shares during the period. First Trust Advisors LP lifted its stake in shares of Charles River Laboratories Intl. by 28.0% in the fourth quarter. First Trust Advisors LP now owns 1,099,399 shares of the medical research company’s stock valued at $124,430,000 after buying an additional 240,437 shares during the period. Brown Advisory Inc. lifted its stake in shares of Charles River Laboratories Intl. by 1.0% in the fourth quarter. Brown Advisory Inc. now owns 799,228 shares of the medical research company’s stock valued at $90,457,000 after buying an additional 7,663 shares during the period. Norges Bank bought a new stake in shares of Charles River Laboratories Intl. in the fourth quarter valued at about $61,460,000. Finally, Dimensional Fund Advisors LP lifted its stake in Charles River Laboratories Intl. by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 508,313 shares of the medical research company’s stock worth $73,830,000 after purchasing an additional 2,978 shares during the period. 94.72% of the stock is currently owned by hedge funds and other institutional investors.

CRL opened at $131.97 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.63 and a quick ratio of 1.39. Charles River Laboratories Intl. Inc has a 52 week low of $103.00 and a 52 week high of $149.07. The firm has a market cap of $6.48 billion, a price-to-earnings ratio of 21.89, a price-to-earnings-growth ratio of 1.71 and a beta of 1.05.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Tuesday, May 7th. The medical research company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.38 by $0.02. Charles River Laboratories Intl. had a net margin of 9.63% and a return on equity of 23.03%. The firm had revenue of $604.57 million during the quarter, compared to analyst estimates of $587.65 million. During the same quarter in the previous year, the business earned $1.29 EPS. The business’s quarterly revenue was up 22.4% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories Intl. Inc will post 6.48 EPS for the current year.

In other Charles River Laboratories Intl. news, Director George Massaro sold 3,140 shares of Charles River Laboratories Intl. stock in a transaction on Friday, May 10th. The shares were sold at an average price of $134.64, for a total transaction of $422,769.60. Following the completion of the sale, the director now owns 15,344 shares of the company’s stock, valued at approximately $2,065,916.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William D. Barbo sold 4,905 shares of Charles River Laboratories Intl. stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $125.16, for a total transaction of $613,909.80. Following the sale, the insider now directly owns 25,859 shares of the company’s stock, valued at approximately $3,236,512.44. The disclosure for this sale can be found here. Insiders have sold a total of 9,047 shares of company stock valued at $1,168,322 in the last ninety days. Company insiders own 1.80% of the company’s stock.

CRL has been the subject of a number of analyst reports. Barclays raised their price target on shares of Charles River Laboratories Intl. from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, March 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a $162.00 price objective on shares of Charles River Laboratories Intl. in a report on Thursday, February 14th. KeyCorp raised their price target on shares of Charles River Laboratories Intl. from $140.00 to $151.00 and gave the company an “overweight” rating in a report on Monday, March 11th. Zacks Investment Research lowered shares of Charles River Laboratories Intl. from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Finally, Wolfe Research started coverage on shares of Charles River Laboratories Intl. in a report on Tuesday, April 2nd. They issued a “market perform” rating for the company. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and a consensus target price of $146.27.

TRADEMARK VIOLATION WARNING: This piece was reported by Riverton Roll and is the property of of Riverton Roll. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://rivertonroll.com/news/2019/06/14/principal-financial-group-inc-boosts-stake-in-charles-river-laboratories-intl-inc-nysecrl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: What is a good rate of return for a mutual fund?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.